Search results
6 days ago · Jump into OrbitonX game and become a crypto guru! 💸 +50 tokens as a welcome gift. 🔥 +100 tokens if you have Telegram Premium. Join a GameFi journey where crypto portfolios turn into thrilling competitions. In Treatment 4x09. Eladio - Week 3 (Season 4 Episode 9) Subtitles for this episode: English subtitles. 0/0. In Treatment 4x09 (WEB) WEB.
5 days ago · This is the latest treatment NICE has recommended for multiple myeloma, with three other drugs also recommended in 2024. Its use through the Cancer Drugs Fund will give people access to this promising new fourth-line treatment while longer-term data on its use is collected to establish whether it is clinically and cost effective.
2 days ago · Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Verzenio and for 3 weeks after the last dose. Based on findings in animals, Verzenio may impair fertility in males of reproductive potential.
3 days ago · Purpose FOLFOXIRI is a standard treatment for unresectable colorectal cancer (CRC) liver metastases. However, limited data exists on its safety and effectiveness in low-to-middle-income countries (LMICs). This prospective study addresses this gap in a Vietnamese LMIC setting. Methods We enrolled 92 patients with unresectable CRC liver metastases between 2022 and 2023. All patients received ...
3 days ago · Blood Podcast - Season 8, Episode 18 | Blood | American Society of Hematology. Update on fixed-dose venetoclax-obinutuzumab in previously untreated CLL; dual epi-immunotherapy in cHL; predicting treatment failure in TKI-treated CML. In this week's episode we'll learn about the updated phase 3 results on fixed-dose venetoclax plus obinutuzumab ...
6 days ago · Download In Treatment 4x17 subtitles. english subtitles. Read us on: episode title: Eladio - Week 5. episode number: Season 4 episode 17. rip: WEB.
3 days ago · This ‘triplet therapy’ doubled the length of time before the cancer progresses, compared to a targeted treatment currently on the NHS. The team, based at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust, hope the results will lead to the licencing of a new drug called inavolisib.
